Mounjaro vs Saxenda: Which Weight Loss Injection Is Right for You?
Find the Right Treatment for You
Our GPhC-registered pharmacist independent prescribers will assess which treatment is most appropriate for your individual circumstances.
Start Your Consultation →Quick Overview
| Feature | 💉 Mounjaro (tirzepatide) | 💉 Saxenda (liraglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| Injection frequency | Once weekly | Once daily |
| Average weight loss | ~20.9% body weight | ~8% body weight |
| MHRA approval (weight) | 2023 | 2017 |
| Starting dose | 2.5mg weekly | 0.6mg daily |
| Maximum dose | 15mg weekly | 3mg daily |
| Trial duration (peak data) | 72 weeks | 56 weeks |
How They Work: Mechanism Comparison
Saxenda (liraglutide) is a GLP-1 receptor agonist — it mimics a single gut hormone that signals fullness to the brain, slows gastric emptying, and stimulates insulin release. It is an effective and well-established treatment with a strong safety record built over nearly a decade of clinical use.
Mounjaro (tirzepatide) activates two gut hormone receptors — GIP in addition to GLP-1. As detailed in our guide to how Mounjaro works, the dual activation produces a synergistic appetite-suppressing effect more powerful than GLP-1 stimulation alone. GIP activation also alters fat metabolism in a complementary way, and the combined insulin response is more robust.
In short: same general principle, meaningfully different execution — and a substantially different outcome.
Efficacy: Weight Loss Results Head-to-Head
| Metric | Mounjaro 15mg (SURMOUNT-1) | Saxenda 3mg (SCALE Obesity) |
|---|---|---|
| Average body weight loss | 20.9% | 8.0% |
| Lost ≥5% body weight | 91% | 63% |
| Lost ≥10% body weight | 79% | 33% |
| Lost ≥15% body weight | 66% | ~16% |
| Lost ≥20% body weight | 57% | <5% |
| Trial duration | 72 weeks | 56 weeks |
| vs placebo | +17.8% additional weight loss | +5.4% additional weight loss |
Important context: These are different trials with different patient populations — not a direct head-to-head. Both required lifestyle changes. Results vary between individuals. The purpose of this comparison is to illustrate the scale of difference in efficacy; individual outcomes depend on starting weight, adherence, dose reached, and lifestyle changes maintained.
Dosing & Administration
| Dosing aspect | Mounjaro | Saxenda |
|---|---|---|
| Injection frequency | Once weekly (same day each week) | Once daily (any time of day) |
| Starting dose | 2.5mg weekly | 0.6mg daily |
| Escalation schedule | +2.5mg every 4 weeks | +0.6mg every week |
| Maximum dose | 15mg weekly | 3mg daily |
| Injection sites | Abdomen, thigh, upper arm | Abdomen, thigh, upper arm |
| Device | Pre-filled autoinjector pen | Pre-filled dial-a-dose pen |
| Storage | Refrigerate; 30 days at room temp | Refrigerate; 30 days at room temp |
The once-weekly convenience of Mounjaro is a significant practical advantage for many patients. Missing a daily injection is easier than missing a weekly one — and weekly dosing means fewer injection-related decisions and less disruption to daily routine.
Side Effects: How Do They Compare?
Both medications share a broadly similar gastrointestinal side effect profile — a consequence of their shared GLP-1 mechanism:
| Side effect | Mounjaro | Saxenda |
|---|---|---|
| Nausea | Very common (≥1 in 10) | Very common (≥1 in 10) |
| Vomiting | Common (≥1 in 100) | Common (≥1 in 100) |
| Diarrhoea | Very common | Very common |
| Constipation | Common | Common |
| Decreased appetite | Very common (intended effect) | Very common (intended effect) |
| Pancreatitis (rare) | Uncommon — monitor | Uncommon — monitor |
| Gallbladder disease | Uncommon | Uncommon |
| Injection site reactions | Common | Common |
Gastrointestinal side effects are most common during dose escalation and typically improve significantly as the body adjusts. See our dedicated guide: Mounjaro side effects: what to expect and how to manage them.
Eligibility: Who Can Take Each?
Eligibility criteria are very similar for both treatments — both follow NICE guidance on obesity pharmacotherapy:
- BMI ≥ 30, or
- BMI 27–29.9 with at least one weight-related comorbidity
- Both must be used alongside a calorie-reduced diet and increased activity
- Neither is suitable during pregnancy or breastfeeding
- Neither should be combined with the other, or with other GLP-1/GIP agonists
Which Is Better for Type 2 Diabetes?
If you have both obesity and type 2 diabetes, Mounjaro has demonstrated superior performance on both fronts in clinical trials. The SURPASS programme specifically studied tirzepatide in people with type 2 diabetes, consistently showing greater HbA1c reductions and greater weight loss than semaglutide, liraglutide, and other comparators.
Mounjaro is now licensed for type 2 diabetes management as well as weight loss in the UK — making it potentially the more appropriate choice for people managing both conditions simultaneously. Your prescriber will guide this decision based on your current diabetes treatment, HbA1c, and overall medication profile.
Can I Switch from Saxenda to Mounjaro?
Yes — switching from Saxenda to Mounjaro is possible, but it must be done under medical supervision. You should not take both simultaneously. Key considerations:
- Stop Saxenda before starting Mounjaro — your prescriber will advise on the appropriate interval
- Begin Mounjaro at the initiation dose (2.5mg weekly) regardless of your previous Saxenda dose
- Expect a brief transition period where appetite suppression may feel different as your system adapts to the new mechanism
- Update your prescriber on all current medications — both act on blood sugar in people with diabetes and monitoring may need adjustment
The Verdict: Which Should You Choose?
On pure efficacy grounds, Mounjaro is clearly the more powerful treatment for the majority of eligible adults. Its dual mechanism consistently produces more than double the weight loss of liraglutide in clinical trials, with a comparable tolerability profile and the practical convenience of once-weekly dosing.
However, Saxenda remains a valid and clinically meaningful option for people who:
- Prefer daily dosing for more granular control
- Have used Saxenda successfully and are maintaining well
- Have specific contraindications to tirzepatide not present with liraglutide
- Are under the care of a clinician who recommends it based on individual history
The right choice is always made in the context of a full medical consultation — not from a comparison article alone. Access Doctor’s GPhC-registered pharmacist independent prescribers will assess your eligibility and recommend the most appropriate treatment for your individual circumstances.
💉 Prescription Weight Loss
Mounjaro (Tirzepatide)
MHRA-approved once-weekly injection. Dual GIP & GLP-1 action — the most effective injectable weight loss treatment currently available in the UK.
View weight loss treatments →Get Expert Guidance on the Right Treatment
Complete a free online consultation — our GPhC-registered pharmacist independent prescribers will recommend the right weight loss treatment for your circumstances.
View Weight Loss Treatments →Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Mounjaro (tirzepatide) is a prescription-only medicine in the UK — always complete a full medical consultation before starting treatment. Always consult a qualified healthcare professional regarding your individual circumstances. In a medical emergency, call 999.
Frequently Asked Questions
Is Mounjaro better than Saxenda for weight loss?
Yes — clinical evidence shows Mounjaro produces significantly greater average weight loss (20.9%) than Saxenda (8%). The dual GIP and GLP-1 mechanism of tirzepatide is more effective than GLP-1 action alone. However, both are MHRA-approved and clinically valid options assessed individually during consultation.
Is Saxenda or Mounjaro better for type 2 diabetes?
Mounjaro has demonstrated superior blood glucose control alongside greater weight loss in clinical trials involving people with type 2 diabetes. For most people with both conditions, Mounjaro is the more effective option if clinically appropriate — your prescriber will advise based on your individual profile.
Can I switch from Saxenda to Mounjaro?
Yes, but this must be done under medical supervision. Stop Saxenda before starting Mounjaro — your prescriber will advise on the appropriate interval. Begin Mounjaro at the 2.5mg initiation dose regardless of your previous Saxenda dose. Never take both simultaneously.
Which has fewer side effects: Mounjaro or Saxenda?
Both have broadly similar gastrointestinal side effect profiles. Mounjaro’s weekly injection schedule means side effects occur less frequently than with Saxenda’s daily injection. Overall tolerability is comparable, though individual responses vary. Side effects are most common during dose escalation.
Why might a prescriber choose Saxenda over Mounjaro?
Saxenda has a longer established track record (licensed since 2017), may be preferred for people who want daily dosing, and suits people already doing well on it. Prescriber guidance will be based on individual medical history, response, and preference — not solely on efficacy data.
What is the price difference between Mounjaro and Saxenda?
Mounjaro is generally more expensive per pen than Saxenda. However, given its significantly greater efficacy, cost-per-kilogram lost may be comparable or lower over time. Current pricing for both treatments is available during your consultation with Access Doctor.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387:205–216. Available at: nejm.org
- Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity). NEJM. 2015;373:11–22. Available at: nejm.org
- NICE. Tirzepatide for managing overweight and obesity (TA1026). Available at: nice.org.uk/guidance/ta1026
- NICE. Liraglutide for managing overweight and obesity (TA664). Available at: nice.org.uk/guidance/ta664
- Frias JP, et al. Tirzepatide versus Semaglutide in Type 2 Diabetes (SURPASS-2). NEJM. 2021;385:503–515. Available at: nejm.org